384 related articles for article (PubMed ID: 25263445)
1. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
[TBL] [Abstract][Full Text] [Related]
2. Ginkgoic acid impedes gastric cancer cell proliferation, migration and EMT through inhibiting the SUMOylation of IGF-1R.
Liu D; Li Z; Yang Z; Ma J; Mai S
Chem Biol Interact; 2021 Mar; 337():109394. PubMed ID: 33508304
[TBL] [Abstract][Full Text] [Related]
3. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
4. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
5. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
6. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
7. Sumoylation dynamics during keratinocyte differentiation.
Deyrieux AF; Rosas-Acosta G; Ozbun MA; Wilson VG
J Cell Sci; 2007 Jan; 120(Pt 1):125-36. PubMed ID: 17164289
[TBL] [Abstract][Full Text] [Related]
8. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
9. Effect of endosulfan and bisphenol A on the expression of SUMO and UBC9.
Yarahalli Jayaram V; Baggavalli S; Reddy D; Sistla S; Malempati R
Drug Chem Toxicol; 2020 Nov; 43(6):637-644. PubMed ID: 30426790
[TBL] [Abstract][Full Text] [Related]
10. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9.
Li Z; Wu S; Wang J; Li W; Lin Y; Ji C; Xue J; Chen J
Int J Mol Med; 2012 Nov; 30(5):1053-60. PubMed ID: 22895527
[TBL] [Abstract][Full Text] [Related]
12. Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.
Truong K; Lee TD; Chen Y
J Biol Chem; 2012 May; 287(19):15154-63. PubMed ID: 22403398
[TBL] [Abstract][Full Text] [Related]
13. Ang II Promotes SUMO2/3 Modification of RhoGDI1 Through Aos1 and Uba2 Subunits, and then Regulates RhoGDI1 Stability and Cell Proliferation.
Qi Y; Guan H; Liang X; Sun J; Yao W
Cardiovasc Drugs Ther; 2021 Aug; 35(4):769-773. PubMed ID: 33891248
[TBL] [Abstract][Full Text] [Related]
14. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2.
Hirohama M; Kumar A; Fukuda I; Matsuoka S; Igarashi Y; Saitoh H; Takagi M; Shin-ya K; Honda K; Kondoh Y; Saito T; Nakao Y; Osada H; Zhang KY; Yoshida M; Ito A
ACS Chem Biol; 2013 Dec; 8(12):2635-42. PubMed ID: 24143955
[TBL] [Abstract][Full Text] [Related]
15. HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44(+)/CD24(-/low) tumor-initiating subpopulation in basal-like breast cancer.
So JY; Wahler J; Das Gupta S; Salerno DM; Maehr H; Uskokovic M; Suh N
J Steroid Biochem Mol Biol; 2015 Apr; 148():111-21. PubMed ID: 25541438
[TBL] [Abstract][Full Text] [Related]
16. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
Citro S; Chiocca S
Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
[TBL] [Abstract][Full Text] [Related]
18. Starting and stopping SUMOylation. What regulates the regulator?
Watts FZ
Chromosoma; 2013 Dec; 122(6):451-63. PubMed ID: 23812602
[TBL] [Abstract][Full Text] [Related]
19. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Latent Membrane Protein-1 Induces the Expression of SUMO-1 and SUMO-2/3 in LMP1-positive Lymphomas and Cells.
Salahuddin S; Fath EK; Biel N; Ray A; Moss CR; Patel A; Patel S; Hilding L; Varn M; Ross T; Cramblet WT; Lowrey A; Pagano JS; Shackelford J; Bentz GL
Sci Rep; 2019 Jan; 9(1):208. PubMed ID: 30659232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
